Skye Bioscience, Inc.
SKYE
$2.23
$0.3518.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.16% | -75.59% | -110.50% | -141.19% | -0.20% |
| Total Depreciation and Amortization | 13.80% | 60.29% | 142.18% | 373.45% | 428.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | -86.36% |
| Total Other Non-Cash Items | 156.03% | 70.75% | 142.00% | 573.35% | -84.97% |
| Change in Net Operating Assets | -71.24% | 514.01% | 280.02% | 143.09% | 226.94% |
| Cash from Operations | -16.31% | -42.81% | -70.63% | -98.33% | -69.37% |
| Capital Expenditure | 100.00% | 100.00% | 99.61% | 96.39% | -3,293.75% |
| Sale of Property, Plant, and Equipment | 48.88% | 69.65% | -73.44% | -73.63% | -73.57% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 191.93% | 130.02% | -- | -- | -- |
| Cash from Investing | 189.17% | 129.62% | -7,839.86% | -4,741.52% | -1,295.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -92.50% | -93.41% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.28% | 100.46% | 100.46% | -2,320.29% | -2,266.73% |
| Cash from Financing | -776.89% | 98.00% | -99.96% | -99.97% | -99.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 73.43% | 16.80% | -207.67% | -193.21% | -171.83% |